From Prior Authorization to Clinical Pathways: The Growing Role of AI in Payer Strategy
There is no doubt that payers in the U.S. are investing heavily in AI, but there is much uncertainty about how this technology is currently deployed. While the industry’s AI conversation has focused on generative tools and administrative efficiency, payers are increasingly deploying AI in utilization management, clinical pathways and contracting. According to research from […]
Market Access in 2026: Predictions on Policies, Contracting and AI
To better understand what 2026 might bring, we asked three MMIT market access experts to share their perspectives on upcoming market shifts. Read the first of this two-part series for key insights into the year ahead. 1. What’s the biggest challenge for manufacturers launching new products this year? Steve Callahan, Senior Director, Advisory & Insights: […]
Faster Insights or Faster Fail? How to Avoid the Misuse of Real-World Data with AI
As artificial intelligence (AI) transforms how life sciences organizations access and analyze real-world data (RWD), one challenge looms large: ensuring that these powerful tools are used appropriately. RWD can illuminate patient outcomes, accelerate research, and guide better decision-making—but only when it’s handled ethically, transparently, and within the boundaries of contractual and regulatory use. Here are some ways to […]
Tracking the Real-World Impact of Payer Policies on Patient Outcomes
In today’s complex pharmaceutical landscape, a brand’s market access can no longer be judged solely by its coverage. Pharma leaders are under growing pressure not just to identify access barriers, but to prove their impact. They want the ability to link payer policy decisions to patient outcomes, as their payer strategies and competitive positioning depend […]
Pharma’s Real-World Data Dilemma: Strategic Asset or Wasted Resource?
This article was originally published in BioPharma Dive. Every day, patients are experiencing the life-changing impact of real-world data (RWD), and life sciences companies are feeling the business impact, too. RWD is no doubt helping pharma companies better understand the patient journey and get life-saving therapies to market faster, according to Norstella’s recent survey of […]
GenAI and RWD in Pharma: 4 Questions to Fuel Effective Insights
This article was originally published in BioPharma Dive. Generative AI (GenAI) has become one of the most talked-about innovations in healthcare analytics, but for life sciences organizations, simply deploying an AI-powered solution is not enough. To truly unlock the power of real-world data (RWD), GenAI must go beyond checking a box or riding the latest […]
Asembia Trends: IRA Operationalization and the Future of Specialty Therapies
At the end of April, more than 8,000 attendees visited Las Vegas for the Asembia Specialty Pharmacy Summit, otherwise known as AXS25. If you missed the conference, here’s an overview of some of the key areas covered this year: Keeping an Eye on Government Policies AXS25 featured quite a few presentations on the impact of the […]
Mining the Hidden Gems in Unstructured EMR Data
This article was originally published in BioPharma Dive. Pharma companies are increasingly turning to real-world data to answer their commercial business questions, but not all realize that unstructured EMR data is the unsung hero of most queries. Whether a manufacturer is struggling to find a niche patient population, conduct unbiased outcomes research, or generate persuasive […]
How Physicians and Oncologists View AI Assistance
The progressive integration of AI within medicine is transforming the way physicians evaluate and monitor disease, enabling earlier detection and improving outcomes and quality of care. Medical practices are increasingly leveraging datasets, algorithms, and other machine learning techniques to identify subtle patterns that might not be discernable to physicians without this technology. These AI tools […]
What’s Ahead for Market Access in 2025?
As the pharma industry continues to adjust to the provisions of the Inflation Reduction Act (IRA), the country will soon be ushering in a new presidential administration—leaving the future of the IRA in question. Despite ongoing regulatory uncertainty, manufacturers will still be focused on the same concerns: drug development, pipeline performance and ensuring patient access […]